Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q4CX
|
|||
| Former ID |
DIB000725
|
|||
| Drug Name |
MLN-3126
|
|||
| Synonyms |
CCR9 antagonist (oral, Crohn's disease), Millennium
Click to Show/Hide
|
|||
| Indication | Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0; ICD-9: 710.2] | Phase 1 | [1] | |
| Company |
Millennium Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 9 (CCR9) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02209506) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants. U.S. National Institutes of Health. | |||
| REF 2 | Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29. | |||
| REF 3 | GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs. 2010 Jul;13(7):472-81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.